CA3057415A1 - Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators - Google Patents

Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators Download PDF

Info

Publication number
CA3057415A1
CA3057415A1 CA3057415A CA3057415A CA3057415A1 CA 3057415 A1 CA3057415 A1 CA 3057415A1 CA 3057415 A CA3057415 A CA 3057415A CA 3057415 A CA3057415 A CA 3057415A CA 3057415 A1 CA3057415 A1 CA 3057415A1
Authority
CA
Canada
Prior art keywords
optionally substituted
alkyl
halo
compound according
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3057415A
Other languages
English (en)
French (fr)
Inventor
Jane Brown
Stephen Connolly
Steffen V. F. Hansen
Gavin MILNE
Bharat SHIMPUKADE
Don Smyth
Gerard Thomas
Trond Ulven
Matjaz BRVAR
Aaron Rigby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Caldan Therapeutics Ltd
Original Assignee
Caldan Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caldan Therapeutics Ltd filed Critical Caldan Therapeutics Ltd
Publication of CA3057415A1 publication Critical patent/CA3057415A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
CA3057415A 2017-03-24 2018-03-26 Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators Pending CA3057415A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1704714.3 2017-03-24
GBGB1704714.3A GB201704714D0 (en) 2017-03-24 2017-03-24 Pharmaceutical compounds
PCT/GB2018/000047 WO2018172727A1 (en) 2017-03-24 2018-03-26 Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators

Publications (1)

Publication Number Publication Date
CA3057415A1 true CA3057415A1 (en) 2018-09-27

Family

ID=58687800

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3057415A Pending CA3057415A1 (en) 2017-03-24 2018-03-26 Tetrahydro-benzo[d]azepine derivatives as gpr120 modulators

Country Status (12)

Country Link
US (1) US11220483B2 (enExample)
EP (1) EP3601229B1 (enExample)
JP (1) JP7099672B2 (enExample)
KR (1) KR102636166B1 (enExample)
CN (1) CN110891938B (enExample)
AU (1) AU2018238102B2 (enExample)
BR (1) BR112019019868A2 (enExample)
CA (1) CA3057415A1 (enExample)
GB (1) GB201704714D0 (enExample)
MX (1) MX394818B (enExample)
WO (1) WO2018172727A1 (enExample)
ZA (1) ZA201906873B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3781556B1 (en) 2018-04-19 2025-06-18 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
CN118221646A (zh) 2018-07-13 2024-06-21 吉利德科学公司 Pd-1/pd-l1抑制剂
KR102635333B1 (ko) 2018-10-24 2024-02-15 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
EP4153589A4 (en) 2020-05-19 2024-06-12 Kallyope, Inc. AMPK ACTIVATORS
WO2021263039A1 (en) 2020-06-26 2021-12-30 Kallyope, Inc. Ampk activators
CN114163426B (zh) * 2020-09-10 2024-03-19 上海爱博医药科技有限公司 苯并含氧杂环类化合物及其医药应用
JP7214053B2 (ja) * 2020-10-08 2023-01-27 イーライ リリー アンド カンパニー 糖尿病治療に有用な６－メトキシ－３，４－ジヒドロ－１ｈ－イソキノリン化合物
CN114671827B (zh) * 2020-12-24 2024-09-20 杭州百新生物医药科技有限公司 邻苯甲酰磺酰亚胺类衍生物及其应用
KR102605163B1 (ko) * 2021-06-01 2023-11-23 연세대학교 산학협력단 뇌암의 예방 또는 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005282721A1 (en) * 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
JP2009504759A (ja) 2005-08-16 2009-02-05 メモリ ファーマセチカル コーポレーション ホスホジエステラーゼ１０阻害剤
CN101360743A (zh) 2006-01-30 2009-02-04 Irm责任有限公司 作为ppar调节剂的多环的1,2,3,4-四氢-异喹啉衍生物和包含它们的组合物
ATE528306T1 (de) * 2006-11-02 2011-10-15 Piramal Life Sciences Ltd Benzoxazepin-verbindungen, ihre herstellung und verwendung
JP2010519258A (ja) * 2007-02-22 2010-06-03 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｇタンパク質共役受容体のモジュレーターとしてのチアゾール誘導体
WO2009147990A1 (ja) * 2008-06-02 2009-12-10 萬有製薬株式会社 新規イソオキサゾール誘導体
WO2013019682A1 (en) 2011-07-29 2013-02-07 Tempero Pharmaceuticals, Inc. Compounds and methods
US10100042B2 (en) 2014-08-08 2018-10-16 Merck Sharp & Dohme Corp. [5,6]—fused bicyclic antidiabetic compounds
EP3177282B1 (en) 2014-08-08 2021-10-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
CN107567443B (zh) * 2014-12-24 2023-04-28 株式会社Lg化学 作为gpr120激动剂的联芳基衍生物
WO2017201683A1 (en) 2016-05-25 2017-11-30 Merck Sharp & Dohme Corp. Substituted tetrahydroisoquinoline compounds useful as gpr120 agonists

Also Published As

Publication number Publication date
RU2019133659A (ru) 2021-04-26
AU2018238102A2 (en) 2019-11-07
GB201704714D0 (en) 2017-05-10
JP7099672B2 (ja) 2022-07-12
AU2018238102A1 (en) 2019-10-31
KR20190140936A (ko) 2019-12-20
US11220483B2 (en) 2022-01-11
EP3601229B1 (en) 2024-11-06
AU2018238102B2 (en) 2021-11-04
ZA201906873B (en) 2022-03-30
CN110891938A (zh) 2020-03-17
RU2019133659A3 (enExample) 2021-07-16
BR112019019868A2 (pt) 2020-04-22
KR102636166B1 (ko) 2024-02-13
WO2018172727A1 (en) 2018-09-27
EP3601229A1 (en) 2020-02-05
CN110891938B (zh) 2023-10-31
MX2019011314A (es) 2020-01-27
US20200317619A1 (en) 2020-10-08
MX394818B (es) 2025-03-24
JP2020515636A (ja) 2020-05-28

Similar Documents

Publication Publication Date Title
AU2018238102B2 (en) Tetrahydro-benzo(d)azepine derivatives as GPR120 modulators
AU2015274781B2 (en) Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof
CN111801324A (zh) 甲状腺激素受体激动剂及其用途
JP2022547716A (ja) 二機能性分解誘導薬及びそれらの使用方法
JP2012520868A (ja) ３−オキサ−７−アザビシクロ［３．３．１］ノナン
CA2891535A1 (en) Dihydropyrazole gpr40 modulators
JP6491751B2 (ja) Ｌｐ−ＰＬＡ２阻害剤として用いられるピリミジノン系化合物およびその薬物組成物
EA030561B1 (ru) Тетразолон-замещенные дигидропиридиноновые ингибиторы mgat2
EP3114121A1 (en) Dihydropyridinone mgat2 inhibitors for use in the treatment of metabolic disorders
CN118496217A (zh) α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
WO2012173174A1 (ja) アザスピロアルカン化合物
AU2015256038B2 (en) Pyrrolidine GPR40 modulators for the treatment of diseases such as diabetes
JP2024504352A (ja) ソルチリン活性のモジュレーターとしてのピリジン誘導体
CN113501826B (zh) 作为tdp2的抑制剂的呋喃并喹啉二酮
WO2025021048A1 (zh) 一类多环化合物及其用途
RU2776801C2 (ru) Производные тетрагидробензо[d]азапена в качестве модуляторов as gpr120
EP3129345A1 (en) Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof
WO2014097188A1 (en) Compounds of 2,3-dihydro-4h-1,3-benzoxazine-4-one, method for preparing them and pharmaceutical form comprising them
KR20250004873A (ko) Atp 시트레이트 리아제의 마크로시클릭 억제제
JP2014118368A (ja) アザスピロアルカン化合物を有効成分として含有する血糖低下作用薬
WO2013004617A1 (en) Pyrazolopyridines useful in the treatment of disorders of the central nervous system
CN118546109A (zh) 含氮杂环类化合物及其医药用途
NZ717556B2 (en) Spirocyclic compounds as tryptophan hydroxylase inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220819

EEER Examination request

Effective date: 20220819

EEER Examination request

Effective date: 20220819

EEER Examination request

Effective date: 20220819

EEER Examination request

Effective date: 20220819

EEER Examination request

Effective date: 20220819

EEER Examination request

Effective date: 20220819